ESTABLISHMENT LABS HOLDINGS
ESTANASDAQTrading Snapshot
- Day Range
- $240.97 – $247.26
- 52-Week Range
- $38.38 – $97.59
- Volume
- $2.12B
- Avg Volume
- $2.70B
- Shares Outstanding
- 29.4M
- Next Earnings
- Nov 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $211M
- Last Q Revenue
- $68M
- P/E Ratio
- -48.7
- P/S Ratio
- 7.6x
- EPS (TTM)
- $-1.29
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +2.3%
Why Investors Own ESTA
- ✓High-growth profile — revenue up +13.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 28% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ESTABLISHMENT LABS HOLDINGS
ESTA
StockOtter · stockotter.spaceAbout ESTABLISHMENT LABS HOLDINGS
Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants
NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and r
Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives Average Rating of “Moderate Buy” from Brokerages
Shares of Establishment Labs Holdings Inc. (NASDAQ: ESTA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the nine research firms that are presently covering the firm, MarketBeat reports. On
Establishment Labs: Procedure Economics Strengthens The Bull Case
Establishment Labs is leveraging FDA approval and U.S. market entry to drive higher-margin growth through procedure-based offerings like Preservé. Q2 2026 results showed 31.7% revenue growth, gross margin expansion to 70
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture P
Deutsche Bank AG Buys New Holdings in Establishment Labs Holdings Inc. $ESTA
Deutsche Bank AG purchased a new position in shares of Establishment Labs Holdings Inc. (NASDAQ: ESTA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission
Establishment Labs Holdings Inc. (ESTA) Q2 2026 Earnings Call Transcript
Establishment Labs Holdings Inc. (ESTA) Q2 2026 Earnings Call Transcript